Skip to content

Sildenafil citrate for the treatment of asymmetrical intrauterine growth restriction: A randomized controlled trial

Sildenafil citrate for the treatment of asymmetrical intrauterine growth restriction: A randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201705002278236
Enrollment
80
Registered
2017-05-08
Start date
2017-05-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Intrauterine growth restriction

Interventions

Sildenafil citrate

Sponsors

Ain Shams university
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Pregnant Women diagnosed as IUGR. 2.Patients aged between 20¿40 years old. 3.Consenting to participate.

Exclusion criteria

Exclusion criteria: 1.Severe preeclampsia with a diastolic blood pressure ¿ 110 mmHg on two occasions or systolic blood pressure ¿ 160 mmHg on two occasions and that, together with significant proteinuria (at least 1g/litre). 2.Fetus with reversed UA end diastolic flow. 3.Fetus diagnosed to have any congenital anomalies. 4.Diabetes mellitus with pregnancy. 5.Any contraindication for conservative management of IUGR as non-reassuring non-stress test (NST). 6.Patients with contraindication for the drugs given as gastric or duodenal ulcer, bleeding tendency and severe hypotension. 7.Smokers.

Design outcomes

Primary

MeasureTime frame
Gain in fetal AC.

Secondary

MeasureTime frame
Number of days between intervention and termination for fetal indication.;Doppler changes in UA, UV and MCA and whether venous circulation or arterial circulation blood flow will be reversed first.;Maternal blood pressure changes.

Countries

Egypt

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026